期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

DNA甲基化与药物效应的表观遗传药理学研究进展 被引量：4

Advances in pharmacoepigenetics:DNA methylation and drug response
原文传递
导出
摘要 除遗传多态性外,DNA序列的表观遗传修饰,也可造成基因表达水平的改变,从而影响个体对药物的反应,造成药物效应的个体差异。表观遗传药理学研究整个环境因素对药物的影响,为临床药物效应的个体差异提供了新的作用机制学说。DNA甲基化是表观遗传修饰的主要机制之一,本文综述了DNA甲基化对药物效应的影响及环境因素对DNA甲基化的影响。 It is found that epigenetic mechanisms can affect gene expression,which provides a new explanation to the phenomenon discovered in recent years that individual differences in drug response could not be explained by genetic polymorphism.Epigenetic mechanism can modify the DNA sequences epigenetially thus change the levels of gene expression.Pharmacoepigenetics which based on the theory and technology of epigenetics and pharmacology provides a new interpretation to this phenomenon.Epigenetic mechanisms are mainly DNA methylation and histone modification and so on.This review described the interaction of DNA methylation and drug response.
作者 刘海燕 袁洪 黄志军 阳国平
机构地区 中南大学湘雅三医院临床药理中心 中南大学药学院
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2012年第2期142-145,共4页 The Chinese Journal of Clinical Pharmacology
基金 国家自然科学基金资助项目(30873126) 国家"重大新药创制"科技重大专项基金资助项目(2009ZX09501-032)
关键词 表观遗传药理学 DNA甲基化 药物效应 药物代谢 pharmacoepigenetics DNA methylation drug response drug metabolize
分类号 R968 [医药卫生—药理学] R969.1 [医药卫生—药理学]
  • 相关文献

参考文献9

  • 1Baker EK, E1 - Osta A. Epigenetic regulation of muhidrug resist- ance 1 gene expression: profiling CpG methylation status using bi- sulphite sequencing [ J]. Methods Mol Biol,2010 ;596 : 183 - 98.
  • 2Tang M J, Tai IT. A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers [ J ]. J Biol Chem, 2007 ; 282 : 34457 - 34467.
  • 3Cheetham S, Tang M J, Mesak F, et al. SPARC promoter hypermeth- ylation in colorectal cancers can be reversed by 5 - aza - 2'deoxycyt- idine to increase SPARC expression and improve therapy response [ J]. Br J Cancer,2008 ;98 : 1810 - 1819.
  • 4Qin T, Jelinek J, Si J,et al. Mechanisms of resistance to 5 - aza - 2'- deoxycytidine in human cancer cell lines [ J ]. Blood, 2009 ; 113:659 - 667.
  • 5Stresemann C, Lyko F. Modes of action of the DNA methyhrans- ferase inhibitors azacytidine and decitabine [ J ]. Int J Cancer, 2008 ; 123:8 - 13.
  • 6Yuan H, Huang Z J, Liu JJ, et al. Influence on metoprolol antihy- pertensive effect of β1 - adrenoceptor gene polymorphism and meth- ylated medication [ J ]. Cell Biol Int,2008 ; 32 ( Suppl. ) : S7.
  • 7Jiang QX, Yuan H, Huang ZJ. DNA methylation might be the epi- genetic molecular mechanism of different antihypertensive efficacy of metoprolol in β1 - AR gene - directed therapy[ J]. Med Hypothe- ses ,2009 ;72:364 - 365.
  • 8Movassagh M, Choy MK, Goddard M,et al. Differential DNA meth- ylation correlates with differential expression of angiogenic factors in human heart failure [ J ]. PloS One,2010 ;5 : 1 - 5.
  • 9Shivendra D Shukla,Annayya R Aroor.Epigenetic effects of ethanol on liver and gastrointestinal injury[J].World Journal of Gastroenterology,2006,12(33):5265-5271. 被引量：12

二级参考文献3

共引文献11

同被引文献43

  • 1Glubb DM,Innocenti F. Mechanisms of genetic reg-ulation in gene expression: examples from drug me-tabolizing enzymes and transporters [J], Wiley In-terdiscip Rev Syst Biol Med, 2011,3(3): 299 _313.
  • 2Kim GH,Ryan JJ, Marsboom G,et al. Epigeneticmechanisms of pulmonary hypertension [ J ]. PulmCirc,2011,1(3) : 347-356.
  • 3Ivanov M,Kacevska M, Ingelman-Sundberg M.Epigenomics and interindividual differences in drugresponse[J], Clin Pharmacol Ther, 2012,92(6):727-736.
  • 4Handy DE,Castro R, Loscalzo J. Epigenetic modi-fications: basic mechanisms and role in cardiovascu-lar disease[JJ. Circulation, 2011,123 (19): 2145 -2156.
  • 5Evison BJ,Bilardi RA,Chiu FC,et al. CpG methyl-ation potentiates pixantrone and doxorubicin-in-duced DNA damage and is a marker of drug sensi-tivity[J], Nucleic Acids Res, 2009 ,37(19) : 6355 -6370.
  • 6Gomez A, Ingelman-Sundberg M. Pharmacoepige-netics : its role in interindividual differences in drugresponse[J], Clin Pharmacol Ther, 2009, 85 (4):426-430.
  • 7Kim KA, Park PW, Lee OJ,et al. Effect ofCYP3A5 . 3 genotype on the pharmacokinetics andpharmacodynamics of amlodipine in healthy Koreansubjects[J]. Clin Pharmacol Ther, 2006,80(6) : 646-656.
  • 8Baker EK, El-Osta A. Epigenetic regulation ofmultidrug resistance 1 gene expression: profilingCpG methylation status using bisulphite sequencing[J]. Methods Mol Biol,2010,596: 183 - 198.
  • 9Kim KA, Park PW, Park JY. Effect of ABCB1(MDRl) haplotypes derived from G2677T/C3435Ton the pharmacokinetics of amlodipine in healthysubjects[J], Br J Clin Pharmacol,2007, 63(1) : 53-58.
  • 10Nakano H,Nakamura Y,Soda H, et al. Methyla-tion status of breast cancer resistance protein detec-ted by methylation-specific polymerase chain reac-tion analysis is correlated inversely with its expres-sion in drug-resistant lung cancer cells[J]. Cancer,2008,112(5): 1122 - 1130.

引证文献4

二级引证文献13

中国临床药理学杂志
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部